Every 10-Q that AIM ImmunoTech Inc. (AIM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AIM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIM filings page.
AIM ImmunoTech Inc., an immuno‑pharma company developing Ampligen and Alferon, reported very limited Q2 2026 revenue of $26 thousand and an operating loss of $3.5 million, compared with a $2.6 million operating loss a year earlier. Net loss for the quarter was $3.8 million, and $6.8 million for the first half of 2026.
Cash and cash equivalents increased to $9.9 million at June 30, 2026 from $3.0 million at December 31, 2025, driven by $14.4 million of net cash provided by equity offerings and warrant exercises in the first six months. Total assets were $12.7 million, with stockholders’ equity improving to $7.7 million from a $9.8 million deficit.
Management states that recurring losses and operating cash outflows of $7.3 million for the first half raise substantial doubt about the company’s ability to continue as a going concern for at least one year. AIM continues to advance Ampligen, including a fully enrolled Phase 2 DURIPANC trial in metastatic pancreatic cancer and preparatory work for a potential Phase 3 study.
AIM ImmunoTech reported a first-quarter 2026 net loss of $3.0M on minimal revenues of $22K, reflecting its development-stage status. Operating expenses fell sharply to $2.2M from $3.6M a year earlier, mainly from lower research and general and administrative costs.
Cash and cash equivalents increased to $5.8M at March 31, 2026 from $3.0M at year-end 2025, helped by equity sales, warrant exercises and a $1.8M Series G preferred stock rights offering. Stockholders’ equity improved from a deficit of $(9.8)M to positive equity of $2.1M, aided by an $8.7M reclassification of Class E and F warrants from liability to equity.
The company still faces significant risk: management notes substantial doubt about its ability to continue as a going concern, with working capital constraints, ongoing losses and stockholders’ equity of $2.1M versus the $6M minimum required to maintain NYSE American listing. It relies on additional financings, including Streeterville promissory notes and at-the-market equity sales, while advancing Ampligen for late-stage pancreatic cancer through the DURIPANC Phase 2 study and planning a Phase 3 trial with Thermo Fisher Scientific’s PPD unit.
AIM ImmunoTech Inc. reported another loss-making quarter while facing serious financial pressures and exchange-listing risks. For the three months ended September 30, 2025, revenue from clinical treatment programs was only $26,000, against operating expenses of $2.5 million, leading to an operating loss of $2.4 million and a net loss of $3.3 million. For the first nine months of 2025, the company recorded a net loss of $9.8 million, compared with $11.4 million a year earlier. Cash and cash equivalents were $2.3 million, while total assets were $5.5 million and total liabilities $11.6 million, resulting in a stockholders’ deficit of $6.1 million. A new warrant liability of $7.3 million was recorded after an August 2025 equity and warrant financing. Management states that recurring losses, a working capital deficit and sub-minimum equity raise substantial doubt about the company’s ability to continue as a going concern. AIM executed a 1-for-100 reverse stock split in June 2025 to address low trading prices, and its stock was reinstated on NYSE American, but it must lift stockholders’ equity to at least $6.0 million by June 11, 2026 to remain in compliance.